Short Interest In Heartware International Declines 13.3%

The most recent short interest data has been released by the NASDAQ for the 04/15/2015 settlement date, which shows a 288,336 share decrease in total short interest for Heartware International Inc ( HTWR), to 1,882,074, a decrease of 13.28% since 03/31/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days (at the average volume) it would take to close out all of the open short positions if every share traded represented a short position being closed. Average daily volume for HTWR at the 04/15/2015 settlement increased to 268,292, as compared to 151,005 at the 03/31/2015 report. That brought "days to cover" down to 7.02, a 51.19% decrease from the 14.37 days to cover calculated at the previous short interest data release.

The below chart shows the historical "days to cover" for HTWR at previous short interest release dates:

START SLIDESHOW:
Top 25 S.A.F.E. Dividend Stocks »

Loading+chart++2015+TickerTech.com

A decreased "days to cover" value could indicate that short sellers are no longer expecting the same decline in stock price they once were, or it could also indicate a long bet elsewhere was closed where HTWR had been shorted as a hedge.

The chart below shows the one year performance of HTWR shares, versus its 200 day moving average. Looking at this chart, HTWR's low point in its 52 week range is $69.05 per share, with $95.90 as the 52 week high point — that compares with a last trade of $74.58.

If you liked this article you might like

Ranking the Activists for Proxy Season 2016

HeartWare (HTWR) Stock Downgraded at Barclays

HeartWare (HTWR) Stock Continues to Surge on Medtronic Deal

Medtronic Acquires HeartWare With Some Activist Inspiration

Jim Cramer on the Medtronic-HeartWare Deal